Long before a person begins to forget names, faces, or familiar places, the brain is already fighting a hidden battle. As nerve cells gradually die and connections between them disappear, the brain attempts to compensate, rerouting signals and recruiting healthy regions to take over lost functions. For years, sometimes decades, this process can unfold unnoticed. By the time memory problems become visible, significant damage may already have occurred.
Now, a new generation of blood tests could change that timeline.
According to a report published by Die Zeit, two blood tests designed for the early detection of Alzheimer’s disease received certification in the European Union in May 2026. Initially approved for use in people already showing signs of dementia, the tests are expected to reach the market as early as July. Researchers and clinicians believe the technology could fundamentally alter how Alzheimer’s is diagnosed and, eventually, how it is treated.
At the center of that possibility is a simple blood sample that may reveal biological signs of Alzheimer’s years before the first symptoms appear.
The promise of earlier detection stands in sharp contrast to the challenges of current diagnostic methods. Today, physicians typically rely on a combination of brain scans, cognitive assessments, and examinations of cerebrospinal fluid. Each approach has limitations.
Magnetic resonance imaging, or MRI, can identify structural changes in the brain, but such changes often become visible only after substantial numbers of nerve cells have already died. PET scans can detect disease-related proteins earlier, but they are expensive, costing around €3,000, and are generally available only in specialized medical centers. Cognitive tests can help identify memory impairment, yet repeated testing may produce practice effects that influence results.
For many patients, diagnosis also involves a lumbar puncture, a procedure in which a needle is inserted between vertebrae to collect cerebrospinal fluid surrounding the brain and spinal cord. While widely used, the procedure can be uncomfortable and occasionally painful.
At Berlin’s Charité University Hospital, psychiatrist Julian Hellmann-Regen has spent the past two years using the new blood tests in research studies and comparing the results with established diagnostic methods. The findings, he says, have been striking.
“They work impressively well,” Hellmann-Regen told Die Zeit, citing a growing body of scientific evidence supporting the tests’ accuracy.
The technology focuses on proteins associated with the development of Alzheimer’s disease. Scientists have long known that amyloid proteins accumulate between nerve cells years before dementia develops. These deposits trigger changes in another protein known as tau, setting off a chain reaction that eventually leads to cell death and cognitive decline.
Researchers have found that a specific form of tau, known as p-Tau217, can be detected in the bloodstream relatively soon after amyloid begins accumulating in the brain. The discovery has generated significant excitement among scientists studying neurodegenerative diseases.
Henrik Zetterberg, a researcher at the UK Dementia Research Institute in London, described p-Tau217 as the most important biomarker currently available for Alzheimer’s disease. Research conducted over recent years has shown a strong correlation between elevated levels of the protein in blood samples and Alzheimer’s-related changes within the brain.
A recent study published in The Lancet found that middle-aged individuals without dementia who showed abnormal levels of amyloid or p-Tau217 performed worse on cognitive tests and were more likely to experience declines in memory over the following five years.
Yet the enthusiasm is tempered by caution.
Researchers acknowledge that the tests remain imperfect. Factors such as genetics and biological sex may influence results, but their effects are not yet fully understood. False positives can also occur, particularly among younger individuals. In some cases, people may test positive for p-Tau217 despite showing no detectable amyloid accumulation in the nervous system.
Perhaps most importantly, scientists still do not know whether every person with amyloid deposits in the brain will eventually develop Alzheimer’s disease. Some may never experience symptoms, while others may die of unrelated causes before dementia emerges.
Those uncertainties have made many clinicians reluctant to use blood tests as standalone diagnostic tools.
Frank Jessen, the Cologne-based psychiatrist who coordinates Germany’s dementia treatment guidelines, told Die Zeit that blood tests are currently recommended only as supplements to other examinations in symptomatic patients. For people without symptoms, routine testing is not yet advised.
Still, evidence continues to accumulate.
Researchers recently reported that tracking p-Tau217 levels over extended periods may significantly improve predictive accuracy. In a study published earlier this year, scientists described the biomarker as an “Alzheimer’s clock,” capable of forecasting when cognitively healthy individuals would develop Alzheimer’s disease within a margin of three to four years.
Such findings have fueled expectations that blood testing could soon become a standard component of dementia screening.
For patients, the impact could be profound.
One case highlighted by Die Zeit involved a 77-year-old man whose personality and memory gradually began to change. Despite troubling symptoms, conventional tests failed to provide a definitive diagnosis. Psychological assessments appeared normal, and initial findings remained inconclusive.
Only after he underwent experimental blood testing at Charité did physicians identify elevated levels of p-Tau217. A subsequent examination of his cerebrospinal fluid confirmed that he had Alzheimer’s disease.
For the patient, certainty proved more valuable than prolonged uncertainty. The diagnosis was difficult to accept, but it replaced months of unanswered questions and growing anxiety.
The emergence of effective blood testing also coincides with a turning point in Alzheimer’s treatment. Until recently, doctors had no therapies that directly targeted the biological causes of the disease. That changed with the approval in the European Union of two amyloid-targeting antibody treatments.
The drugs help the immune system remove amyloid deposits from the brain and have demonstrated the ability to slow disease progression. However, they are expensive, require close medical supervision, and can carry risks including brain swelling and bleeding.
Their greatest potential may lie in earlier intervention.
Scientists are increasingly asking whether treatment could begin before symptoms appear, at a stage when amyloid accumulation is detectable but extensive nerve-cell damage has not yet occurred. Researchers believe that removing amyloid early enough could prevent the tau-related processes that ultimately lead to irreversible brain degeneration.
Studies examining the effectiveness of these therapies in symptom-free individuals are expected to deliver results next year. If successful, they could bring medicine closer to a long-sought objective: identifying and treating Alzheimer’s disease before patients realize anything is wrong.
For now, the prospect remains a vision rather than a reality. Yet with certified blood tests nearing clinical use and new treatments entering practice, the landscape of Alzheimer’s care appears to be entering one of its most significant transitions in decades.
